Celon Pharma Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Celon Pharma stock has a consensus rating of "Hold" and an average price target of zł 20.44. The average 1-year stock price forecast is 4.07% higher than the current stock price, while the lowest is zł 16.00 (-18.53%) and the highest is zł 25.50 (+29.84%).

Price Target: zł 20.44 (+4.07%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	zł 16.00	zł 20.44	zł 21.00	zł 25.50
Change	-18.53%	+4.07%	+6.92%	+29.84%

Analyst Ratings

The average analyst rating for Celon Pharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Nov '25	Jan '26	Mar '26	Apr '26	May '26	Jul '26
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	2	2	2	2	2	2
Total	5	5	5	5	5	5

Financial Forecast

Revenue This Year

290.50M

from 244.34M

18.89%

from 244.34M

Revenue Next Year

288.73M

from 290.50M

-0.61%

from 290.50M

EPS This Year

-0.44

from -1.48

EPS Next Year

-0.18

from -0.44

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	196.09M	193.89M	214.66M	205.55M	244.34M	290.50M
Revenue Growth	24.54%	-1.12%	10.72%	-4.25%	18.87%	18.89%
Operating Income	-10.59M	-37.90M	-28.35M	-52.94M	-24.87M	11.90M
Net Income	-11.61M	-39.28M	-28.12M	-34.45M	-79.36M	10.30M
EPS	-	-	-	-	-1.48	-0.44
Dividend / Share	0.29	0.09	0.08	-	-	0.08
Free Cash Flow	-1.33M	-18.83M	-34.98M	-23.92M	-	-16.55M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is PLN.

Revenue Forecast

Revenue	2026	2027	2028
High	324.6M
Avg	290.5M
Low	263.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	32.9%
Avg	18.9%
Low	7.6%

EPS Forecast

EPS	2026	2027	2028
High	-0.38
Avg	-0.44
Low	-0.50

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-